BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-1893 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-1893\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07269717-11075@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HRS-1893: Phase 2 readout est. (NCT07269717)
DESCRIPTION:HRS-1893\, phase 2.\nStudy: A Phase II Clinical Trial of HRS-18
 93 in the Treatment of Heart Failure With Preserved Ejection Fraction\nEst
 imated primary completion: March 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/hrs-1893#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07269717
URL:https://assetmemo.bio/drug/hrs-1893#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07021963-11075@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-1893: Phase 2 readout est. (NCT07021963)
DESCRIPTION:HRS-1893\, phase 2\, Hypertrophic Cardiomyopathy.\nStudy: A Cli
 nical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic C
 ardiomyopathy\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/hrs-1893#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07021963
URL:https://assetmemo.bio/drug/hrs-1893#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
